Source: Lumiera Health Inc.
  • Lumiera Health (NHP) has signed a distribution agreement with Fideschem International Ltd.
  • The agreement will enable Awaye™ to access the Vietnamese market
  • Fideschem will obtain all regulatory requirements to allow the sales of Awaye™ in Vietnam and manage sales and marketing initiatives for the product
  • Fideschem International PTE Ltd specializes in the retail sale of pharmaceutical and medical products in Southeast Asia
  • Lumiera specializes in the development and commercialization of consumer products for the natural health industry
  • Shares of Lumiera Health (NHP) opened trading at C$0.020

Lumiera Health (NHP) has signed a distribution agreement with Fideschem International Ltd., a Singapore-based company.

The agreement will enable Awaye™ to access the Vietnamese market which has a population of approximately 100 million people.

Carlos Ponce, CEO of Lumiera Health commented on the partnership with Fideschem.

“In addition to our recent announcements that the U.S. Food & Drug Administration (FDA) has published final registration of the company’s National Drug Code (NDC) allowing Awaye™ to be sold as an OTC drug across the US, a market of approximately 330 million people with a pain relief category of US$6 billion, we are working to further expand the market potential for Awaye™. We are very pleased to be working with the Fideschem team in the Vietnamese market which is a market of approximately 100 million people. Based on the market dynamics and the trend to more natural health products and natural pain relief products, the Fideschem team has forecasted tremendous success for Awaye.”

As a part of the agreement, Fideschem will obtain and maintain all regulatory requirements to allow the sales of Awaye™ in Vietnam and then manage all sales and marketing initiatives.

Fideschem and Lumeira forecast sales to begin in 12 months.

Awaye™ provides a new generation of relief from acute and chronic pain by exploiting the CB2 receptors of the endocannabinoid system, the body’s built-in pain and inflammation defence system.

Singapore-based Fideschem International PTE Ltd is a private company that specializes in the retail sale of pharmaceutical and medical products in Southeast Asia.

Lumiera specializes in the development and commercialization of consumer products for the natural health industry. 

Shares of Lumiera Health Inc. (NHP) opened trading at C$0.020.

More From The Market Online

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.

WELL Health and Microsoft to future-proof North American healthcare

WELL Health Technologies (TSX:WELL) and Microsoft (NDAQ:MSFT) sign a five-year deal to expedite healthcare's transition into the digital age.